Brought to you by 
Undisclosed US biotech licenses Vernalis' adenosine antagonist program; partner is Corvus
27 Oct 2021
Executive Summary
An undisclosed private US biotech licensed exclusive global rights to Vernalis PLC's adenosine receptor antagonist program, including lead candidate V81444 (BIIB034), in Phase I/II for Parkinson's disease and ADHD.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Undisclosed US biotech licenses Vernalis' adenosine antagonist program; partner is Corvus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice